CMXHF Company Profile and Key Details

OTC : CMXHF

CSL

$73.75

1.37+1.89%

Open: 4:00 PM

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

CSL Limited (CMXHF) stock surged +1.89%, trading at $73.75 on OTC, up from the previous close of $72.38. The stock opened at $73.81, fluctuating between $66.00 and $73.81 in the recent session.

Stock Snapshot

72.38

Prev. Close

35.32B

Market Cap

Day Low

11.95

P/E Ratio

6.17

EPS (TTM)

4.85

Cash Flow per Share

73.81

Open

478.91M

Number of Shares

73.81

Day High

99.91%

Free Float in %

35.49

Book Value

100

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 18, 2026	73.81	76.24	73.75	73.75	1.95K
Jun 17, 2026	73.00	73.00	72.38	72.38	505
Jun 16, 2026	71.92	74.47	71.92	74.47	41
Jun 15, 2026	75.85	75.85	75.18	75.18	1.63K
Jun 12, 2026	74.14	74.14	74.14	74.14	15.38K
Jun 11, 2026	74.17	74.17	74.17	74.17	1.28K
Jun 10, 2026	71.00	73.80	69.42	73.80	7.57K
Jun 09, 2026	67.95	67.95	67.55	67.55	2.48K
Jun 08, 2026	70.72	70.72	70.66	70.66	629
Jun 05, 2026	66.82	70.54	66.82	70.54	704
Jun 04, 2026	63.84	66.25	63.84	66.25	713
Jun 03, 2026	66.00	66.00	66.00	66.00	570
Jun 01, 2026	70.04	70.04	65.31	66.81	1.6K
May 29, 2026	68.20	68.20	68.20	68.20	268
May 28, 2026	72.33	72.49	70.44	70.44	347
May 27, 2026	68.25	68.88	68.25	68.88	2.38K
May 26, 2026	67.78	72.60	67.78	72.60	3.06K
May 22, 2026	70.70	70.70	70.00	70.00	4.83K
May 21, 2026	70.00	73.55	70.00	73.55	119
May 20, 2026	68.01	71.61	68.00	71.61	4.05K

Contact Details

Melbourne, VIC 3052

Australia

https://www.csl.com.au 613 938 91911

About Company

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Stock Peers

ODTC

Odonate Therapeutics, Inc.$2,849.50 GNMSF

Genmab A/S$268.61 NONOF

Novo Nordisk A/S$144.95 CSLLY

0.75+0.79%

CSL Limited$95.35 UCBJY

-0.06-0.08%

UCB SA$73.15 PHMMF

4.3+16.01%

Pharma Mar, S.A.$31.15 BVNKF

Bavarian Nordic A/S$21.20 NURPF

Neuren Pharmaceuticals Limited$14.00 ELOX

0.05+0.36%

Eloxx Pharmaceuticals, Inc.$13.98 TLPPF

Telix Pharmaceuticals Limited$11.00

Company Overview

CSL Limited (OTC:CMXHF) closed at $73.75 USD, gaining $1.37 (1.89%) from the previous close of $72.38. The stock is currently mid-range between its 52-week high and low $63.84 and $184.09. With a market capitalization of about $35.32 billion, CSL Limited is classified as a large-cap and shows lower-than-market volatility (beta ~0.09). Key stats such as the average daily volume over the past year has been around 2.08 thousand shares, volume is running light vs its 52-week average. Headquartered in Melbourne, VIC, CSL Limited operates in the Healthcare sector and the Biotechnology industry. Led by CEO Gordon Naylor DipCompSc, the company employs approximately 32,698 people and listed since November 18, 2005. CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products.

Technical Performance

Average 10-day trading volume of 3.85 thousand shares is significantly above the 3-month average of 2.13 thousand, indicating heightened recent market interest.

Valuation Metrics

CSL Limited trades at a P/E ratio of 24.31, slightly below the S&P 500 average, with a price-to-sales ratio of 2.21 and a price-to-book ratio of 1.87 suggesting the stock is closer to book value. The P/FCF stands at 10.9, also above market averages.

Dividend & Fair Value

CSL Limited last paid a dividend of 2.92 per share, this equals a trailing yield of roughly 1.28%. Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $248.30. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

CSL Limited earnings surprise history is frequent misses against expectations. The quarter that ended February 10, 2026, missed forecasts by -2.66%. The prior quarter beat by -47.33%. Over the last six quarters, Apple has recorded several small beats. These include -69.29% in February 13, 2024.

Financial & Profitability Overview

Over the trailing twelve months, CSL generated $15.43B in revenue, or $31.75 per share. Gross margin was 51.53%, operating margin 19.18%, and net profit margin 19.46%. Returns are healthy, with ROA at 7.62% and ROE at 15.53%.
On valuation metrics, CSL trades at a P/E of 24.31, P/S of 2.21 and P/B of 1.87. The current ratio is 2.57 and quick ratio is 1.15. Operationally, the company’s inventory turnover is 1.23 and cash conversion cycle is 250.19 days. Debt-to-equity is 0.67, supported by a cash flow-to-debt ratio of 0.30.

Quarterly Financial Highlights

For the quarter ended Jun 30, 2025, CSL posted revenue of $15.43B, down slightly from $14.80B in the prior quarter. Gross profit was $7.95B (margin 51.53%). Operating income was $2.96B (margin 19.2%). Net income was$3.00B (EPS $6.20).
The company ended the quarter with $2.16B in cash and short-term investments, a total debt of $11.50B, and net debt of $9.34B. Total assets were $39.40B, with equity of $19.34B. Financials further reflected stability, with operating cash flow of $3.56B, free cash flow of $2.54B, and capital expenditures of - $1.02B.

Price Forecast & Outlook

Our AI price prediction model suggests that CSL Limited stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term.

Key Takeaways

Valuation shows CSL Limited trading at a premium to the broader market with a P/E of 24.31.

Frequently Asked Questions

What is the current CSL Limited (CMXHF) stock price?

CSL Limited (OTC: CMXHF) stock price is $73.75 in the last trading session. During the trading session, CMXHF stock reached the peak price of $73.81 while $66.00 was the lowest point it dropped to. The percentage change in CMXHF stock occurred in the recent session was 1.89% while the dollar amount for the price change in CMXHF stock was $1.37.

CMXHF's industry and sector of operation?

The OTC listed CMXHF is part of Biotechnology industry that operates in the broader Healthcare sector. CSL Limited designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of CMXHF?

No Data

How CMXHF did perform over past 52-week?

CMXHF's closing price is 32.59% higher than its 52-week low of $63.84 where as its distance from 52-week high of $184.09 is -7.45%.

How many employees does CMXHF have?

Number of CMXHF employees currently stands at 32,698.

Link for CMXHF official website?

Official Website of CMXHF is: https://www.csl.com.au

How do I contact CMXHF?

CMXHF could be contacted at phone 613 938 91911 and can also be accessed through its website. CMXHF operates from 45 Poplar Road, Melbourne, VIC 3052, Australia.

How many shares of CMXHF are traded daily?

CMXHF stock volume for the day was 100 shares. The average number of CMXHF shares traded daily for last 3 months was 2.08K.

What is the market cap of CMXHF currently?

The market value of CMXHF currently stands at $35.32B with its latest stock price at $73.75 and 478.91M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	32698
Beta	0.21
Sales or Revenue	$15.43B
5Y Sales Change%	0.538%
Fiscal Year Ends	June
Sector	Healthcare
Industry	Biotechnology

CMXHF Company Profile and Key Details

CSL

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways